Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma
In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines by combining drug induced growth inhibition and gene expression profiling. In the current report a melphalan resistance profile of 19 genes were weighted by microarray data from the MRC Myeloma IX tri...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 20, 2013
|
| In: |
PLOS ONE
Year: 2013, Jahrgang: 8, Heft: 12 |
| ISSN: | 1932-6203 |
| DOI: | 10.1371/journal.pone.0083252 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1371/journal.pone.0083252 Verlag, lizenzpflichtig, Volltext: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083252 
|
| Verfasserangaben: | Martin Bøgsted, Anders E. Bilgrau, Christopher P. Wardell, Uta Bertsch, Alexander Schmitz, Julie S. Bødker, Malene K. Kjeldsen, Hartmut Goldschmidt, Gareth J. Morgan, Karen Dybkaer, Hans E. Johnsen |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1741584930 | ||
| 003 | DE-627 | ||
| 005 | 20230427060714.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 201201s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1371/journal.pone.0083252 |2 doi | |
| 035 | |a (DE-627)1741584930 | ||
| 035 | |a (DE-599)KXP1741584930 | ||
| 035 | |a (OCoLC)1341382408 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Bøgsted, Martin |e VerfasserIn |0 (DE-588)1222544466 |0 (DE-627)1741586631 |4 aut | |
| 245 | 1 | 0 | |a Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |c Martin Bøgsted, Anders E. Bilgrau, Christopher P. Wardell, Uta Bertsch, Alexander Schmitz, Julie S. Bødker, Malene K. Kjeldsen, Hartmut Goldschmidt, Gareth J. Morgan, Karen Dybkaer, Hans E. Johnsen |
| 264 | 1 | |c December 20, 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 01.12.2020 | ||
| 520 | |a In a conceptual study of drug resistance we have used a preclinical model of malignant B-cell lines by combining drug induced growth inhibition and gene expression profiling. In the current report a melphalan resistance profile of 19 genes were weighted by microarray data from the MRC Myeloma IX trial and time to progression following high dose melphalan, to generate an individual melphalan resistance index. The resistance index was subsequently validated in the HOVON65/GMMG-HD4 trial data set to prove the concept. Biologically, the assigned resistance indices were differentially distributed among translocations and cyclin D expression classes. Clinically, the 25% most melphalan resistant, the intermediate 50% and the 25% most sensitive patients had a median progression free survival of 18, 32 and 28 months, respectively (log-rank P-value = 0.05). Furthermore, the median overall survival was 45 months for the resistant group and not reached for the intermediate and sensitive groups (log-rank P-value = 0.003) following 38 months median observation. In a multivariate analysis, correcting for age, sex and ISS-staging, we found a high resistance index to be an independent variable associated with inferior progression free survival and overall survival. This study provides clinical proof of concept to use in vitro drug screen for identification of melphalan resistance gene signatures for future functional analysis. | ||
| 650 | 4 | |a B cells | |
| 650 | 4 | |a Biomarkers | |
| 650 | 4 | |a Cancers and neoplasms | |
| 650 | 4 | |a Drug screening | |
| 650 | 4 | |a Gene expression | |
| 650 | 4 | |a Hematologic cancers and related disorders | |
| 650 | 4 | |a Microarrays | |
| 650 | 4 | |a Multiple myeloma | |
| 700 | 1 | |a Bilgrau, Anders E. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wardell, Christopher P. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bertsch, Uta |e VerfasserIn |0 (DE-588)1026849861 |0 (DE-627)727494163 |0 (DE-576)372176224 |4 aut | |
| 700 | 1 | |a Schmitz, Alexander |e VerfasserIn |4 aut | |
| 700 | 1 | |a Bødker, Julie S. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kjeldsen, Malene K. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Goldschmidt, Hartmut |d 1956- |e VerfasserIn |0 (DE-588)102258023X |0 (DE-627)717003809 |0 (DE-576)365637386 |4 aut | |
| 700 | 1 | |a Morgan, Gareth J. |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dybkaer, Karen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Johnsen, Hans E. |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t PLOS ONE |d San Francisco, California, US : PLOS, 2006 |g 8(2013,12) Artikel-Nummer e83252, 12 Seiten |h Online-Ressource |w (DE-627)523574592 |w (DE-600)2267670-3 |w (DE-576)281331979 |x 1932-6203 |7 nnas |a Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |
| 773 | 1 | 8 | |g volume:8 |g year:2013 |g number:12 |a Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0083252 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0083252 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20201201 | ||
| 993 | |a Article | ||
| 994 | |a 2013 | ||
| 998 | |g 102258023X |a Goldschmidt, Hartmut |m 102258023X:Goldschmidt, Hartmut |d 910000 |d 910100 |d 50000 |e 910000PG102258023X |e 910100PG102258023X |e 50000PG102258023X |k 0/910000/ |k 1/910000/910100/ |k 0/50000/ |p 8 | ||
| 998 | |g 1026849861 |a Bertsch, Uta |m 1026849861:Bertsch, Uta |d 910000 |d 910100 |e 910000PB1026849861 |e 910100PB1026849861 |k 0/910000/ |k 1/910000/910100/ |p 4 | ||
| 999 | |a KXP-PPN1741584930 |e 3815619637 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Martin Bøgsted, Anders E. Bilgrau, Christopher P. Wardell, Uta Bertsch, Alexander Schmitz, Julie S. Bødker, Malene K. Kjeldsen, Hartmut Goldschmidt, Gareth J. Morgan, Karen Dybkaer, Hans E. Johnsen"]},"relHost":[{"note":["Schreibweise des Titels bis 2012: PLoS ONE","Gesehen am 20.03.19"],"name":{"displayForm":["Public Library of Science"]},"origin":[{"dateIssuedKey":"2006","publisher":"PLOS ; PLoS","publisherPlace":"San Francisco, California, US ; Lawrence, Kan.","dateIssuedDisp":"2006-"}],"part":{"volume":"8","text":"8(2013,12) Artikel-Nummer e83252, 12 Seiten","issue":"12","year":"2013"},"physDesc":[{"extent":"Online-Ressource"}],"corporate":[{"role":"isb","display":"Public Library of Science"}],"title":[{"title_sort":"PLOS ONE","title":"PLOS ONE"}],"language":["eng"],"id":{"issn":["1932-6203"],"eki":["523574592"],"zdb":["2267670-3"]},"type":{"bibl":"periodical","media":"Online-Ressource"},"recId":"523574592","disp":"Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myelomaPLOS ONE","pubHistory":["1.2006 -"]}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2013","dateIssuedDisp":"December 20, 2013"}],"recId":"1741584930","note":["Gesehen am 01.12.2020"],"person":[{"display":"Bøgsted, Martin","role":"aut","given":"Martin","family":"Bøgsted"},{"given":"Anders E.","family":"Bilgrau","role":"aut","display":"Bilgrau, Anders E."},{"display":"Wardell, Christopher P.","role":"aut","family":"Wardell","given":"Christopher P."},{"role":"aut","display":"Bertsch, Uta","given":"Uta","family":"Bertsch"},{"role":"aut","display":"Schmitz, Alexander","given":"Alexander","family":"Schmitz"},{"display":"Bødker, Julie S.","role":"aut","given":"Julie S.","family":"Bødker"},{"given":"Malene K.","family":"Kjeldsen","display":"Kjeldsen, Malene K.","role":"aut"},{"given":"Hartmut","family":"Goldschmidt","display":"Goldschmidt, Hartmut","role":"aut"},{"display":"Morgan, Gareth J.","role":"aut","family":"Morgan","given":"Gareth J."},{"display":"Dybkaer, Karen","role":"aut","given":"Karen","family":"Dybkaer"},{"display":"Johnsen, Hans E.","role":"aut","family":"Johnsen","given":"Hans E."}],"id":{"doi":["10.1371/journal.pone.0083252"],"eki":["1741584930"]},"language":["eng"],"title":[{"title_sort":"Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma","title":"Proof of the concept to use a malignant B cell line drug screen strategy for identification and weight of melphalan resistance genes in multiple myeloma"}]} | ||
| SRT | |a BOEGSTEDMAPROOFOFTHE2020 | ||